Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | EZH2 | Q15910 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SCN1A | P35498 | 1/20 | 0.34 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.34 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10027504 | 0.82 | GAA (0.49) | GAAPOLBEZH2MEN1KMT2A | |
| SCHEMBL11680960 | 0.78 | GAA (0.75) | GAAPOLBHSD17B10GLAEZH2 | |
| SCHEMBL10027482 | 0.78 | GAA (0.45) | GAAALDH1A1 | |
| SCHEMBL2810503 | 0.73 | GAA (0.49) | GAAPOLBHSD17B10EZH2MEN1 | |
| SCHEMBL4917376 | 0.73 | GAA (0.49) | GAAPOLBHSD17B10EZH2MEN1 | |
| SCHEMBL653430 | 0.72 | GAA (0.84) | GAAPOLBHSD17B10GLAEZH2 | |
| SCHEMBL27782632 | 0.72 | GAA (0.47) | GAAPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL134388 | 0.71 | GAA (0.56) | GAAPOLBEZH2MEN1KMT2A | |
| SCHEMBL28472860 | 0.70 | GAA (0.51) | GAAPOLBEZH2MEN1KMT2A | |
| SCHEMBL19559398 | 0.69 | GAA (0.60) | GAAPOLBHSD17B10GLAEZH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9790428-B2 | Piperidine derivative, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2017-10-17 | — | — | US | disclosed |
| US-20170158961-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158961-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | DRD1, PLD1, DRD2 | GAA 4783/4885POLB 1670/4885HSD17B10 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.